Japanese biopharmaceutical firm Takeda Pharmaceutical announced that the company’s drug candidate for leukemia failed to meet the primary endpoint in a late-stage study.

Dr. Reddy’s Laboratories Ltd. along with the company’s subsidiaries announced that Reddy-Lenalidomide, a generic equivalent to Revlimid (lenalidomide) capsules, was approved by Health Canada and launched in the Canadian market.

A U.S. judge said on Sept. 1 he would approve OxyContin maker Purdue Pharma LP’s bankruptcy reorganization plan, clearing a path to resolve thousands of opioid lawsuits and shielding the company’s wealthy Sackler family owners from future opioid litigation.

The U.S. Food and Drug Administration greenlit Janssen’s long-acting, twice-per-year schizophrenia drug Invega Hafyera (paliperidone palmitate six-month).

Novartis AG said on Sept. 1 the company agreed on a deal with Britain’s healthcare service provider for use of the drugmaker’s new anti-cholesterol product Leqvio, after the country’s healthcare cost agency NICE approved the medicine.

Johnson & Johnson announced that the company’s Imbokodo Phase IIb trial in HIV failed to hit the primary endpoint. The study evaluated J&J’s investigational HIV vaccine regimen in young women in sub-Saharan Africa at high risk of acquiring HIV.

An alleged plan by Johnson & Johnson to spin off a company solely responsible for J&J’s talc-based products in order to mitigate lawsuit damages is still on the table following a ruling by a federal judge.

More studies into vaccinated populations show that although antibody responses drop months after vaccination against Covid-19, they still dramatically protect against severe disease and hospitalization. Studies are also continuing on the value and efficacy of booster shots, particularly against the Delta variant.

A booster dose of Johnson & Johnson’s Covid-19 vaccine sharply increased levels of antibodies against the coronavirus, according to interim data from two small, early-stage trials, the company said in a press release on Aug. 25.

The U.S. Food and Drug Administration approved an expanded peripheral artery disease indication for Janssen’s Xarelto (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization due to symptomatic PAD.